Rocket Lab's 650% Five-Year Gain Doesn't Change Near-Term Caution

What happened

Rocket Lab stock has surged over 650% in five years, turning a $5,000 investment into nearly $38,000, driven by strong demand and a record $2.36 billion backlog. However, recent SEC filings and our DeepValue analysis indicate the market is already pricing in successful Neutron first flight and smooth Iridium financing, leaving limited near-term upside at $80 per share. The Q2 2026 10-Q revealed revenue growth of 62% and improved gross margins, but operating losses remain substantial at $57.5 million for the quarter, with negative free cash flow. Critical binary events ahead include completion of Neutron first-stage qualification with a narrowing year-end launch window and finalization of permanent financing for the Iridium acquisition, which still requires multiple approvals. We maintain a WAIT rating, with an attractive entry around $65 and a base case value of $82, as the risk-reward is balanced until these proof points are resolved.

Implication

Despite the impressive five-year return, the current valuation leaves no margin of safety, as the stock already assumes successful execution on Neutron and Iridium financing. The next six months are dominated by two binary events: first-stage qualification for Neutron and a firm first-launch window, and the Iridium deal's permanent financing and regulatory approvals. Until these milestones are achieved, the stock could be volatile, with a bear case of $64 and a bull case of $96. We recommend trimming above $95 and accumulating only near the $65 attractive entry, with a reassessment window of 3-6 months. Key early warning signs include further Neutron schedule slips, increased dilution from Iridium financing, or margin deterioration in Space Systems backlog.

Thesis delta

The thesis remains essentially unchanged: Rocket Lab is a well-executing space company with strong backlog, but at $80 the stock fully prices in near-term success on Neutron and Iridium. The recent news article is retrospective and does not alter the fundamental risk-reward. We continue to see a WAIT rating with no change to conviction or price targets.